LHON患者玻璃体腔注射rAAV2/2-ND4的免疫反应与眼内炎症
该研究为开放标签、剂量递增1/2期随机临床试验的二次分析,纳入15例ND4型Leber遗传性视神经病变患者,单眼玻璃体腔注射rAAV2/2-ND4并随访96周。13例出现眼内炎症,多为轻中度前房炎症和玻璃体炎且对治疗有反应;眼内炎症评分与病毒剂量、血清中和抗体滴度无关。
要点
- 玻璃体腔注射rAAV2/2-ND4后13/15例出现眼内炎症,均为轻中度且治疗有反应。
- 眼内炎症评分与病毒剂量无关,最高评分9.5见于特发性葡萄膜炎病史者。
- 眼内炎症评分与血清中和抗体滴度无关,体液免疫反应与剂量及基线免疫状态无明显关联。
核心结论
- LHON患者玻璃体腔注射rAAV2/2-ND4安全且耐受良好。
- 眼内炎症评分与病毒剂量、血清中和抗体滴度无关。
研究设计与样本
- 开放标签、剂量递增1/2期随机临床试验的二次分析,数据收集自2014年2月13日至2017年3月30日。
- 纳入15例ND4型LHON患者,年龄大于15岁,视力至少为数指,分5个队列。
- 4个剂量队列各3例依次接受9×10^9、3×10^10、9×10^10、1.8×10^11病毒基因组/眼单眼玻璃体腔注射,扩展队列3例接受9×10^10病毒基因组/眼。
- 注射后随访96周,定期眼科检查并采血进行免疫学检测。
主要发现
- 15例患者中13例在rAAV2/2-ND4给药后出现眼内炎症。
- 所有剂量下均报告轻度前房炎症和玻璃体炎,所有病例对治疗有反应。
- 最高眼内炎症评分为9.5,见于有特发性葡萄膜炎病史的患者。
- 治疗前房水中未检测到抗AAV2中和抗体。
- 2例患者在基线和治疗后细胞免疫反应检测为阳性。
关键数值与推荐
- 眼内炎症评分基于前房细胞和闪辉、玻璃体细胞和混浊的分级,参照葡萄膜炎命名标准化计算。
- 细胞免疫反应用酶联免疫斑点法量化,IgG滴度用酶联免疫吸附法测定,中和抗体滴度用荧光素酶法测定。
临床怎么用
- 玻璃体腔注射rAAV2/2-ND4后应监测眼内炎症,尤其是有葡萄膜炎病史的患者。
- 眼内炎症评分与病毒剂量无关,临床监测不应仅依据剂量判断风险。
局限性
- 本文为二次分析,样本量15例,结果解读需谨慎。
- 原文未报告眼内炎症的具体治疗措施及长期视力结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Intravitreal gene therapy is regarded as generally safe with limited mild adverse events, but its systemic effects remain to be investigated. OBJECTIVE: To examine the association between immune response and intraocular inflammation after ocular gene therapy with recombinant adeno-associated virus 2 carrying the ND4 gene (rAAV2/2-ND4). DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of an open-label, dose-escalation phase 1/2 randomized clinical trial of rAAV2/2-ND4 included data from February 13, 2014 (first patient visit), to March 30, 2017 (last patient visit at week 96), the first 2 years after injection. Patients older than 15 years with diagnosed ND4 Leber hereditary optic neuropathy (LHON) and visual acuity of at least counting fingers were enrolled in 1 of 5 cohorts. Four dose cohorts of 3 patients each were treated sequentially. An extension cohort of 3 patients received the dose of 9 × 1010 viral genomes per eye. INTERVENTIONS: Patients received increasing doses of rAAV2/2-ND4 (9 × 109, 3 × 1010, 9 × 1010, and 1.8 × 1011 viral genomes per eye) as a single unilateral intravitreal injection. Patients were monitored for 96 weeks after injection; ocular examinations were performed regularly, and blood samples were collected for immunologic testing. MAIN OUTCOMES AND MEASURES: A composite ocular inflammation score (OIS) was calculated based on grades of anterior chamber cells and flare, vitreous cells, and haze according to the Standardization of Uveitis Nomenclature. The systemic immune response was quantified by enzyme-linked immunospot (cellular immune response), enzyme-linked immunosorbent assay (IgG titers), and luciferase assay (neutralizing antibody [NAb] titers). RESULTS: The present analysis included 15 patients (mean [SD] age, 47.9 [17.2] years; 13 men and 2 women) enrolled in the 5 cohorts of the clinical trial. Thirteen patients experienced intraocular inflammation after rAAV2/2-ND4 administration. Mild anterior chamber inflammation and vitritis were reported at all doses, and all cases were responsive to treatment. A maximum OIS of 9.5 was observed in a patient with history of idiopathic uveitis. Overall, OIS was not associated with the viral dose administered. No NAbs against AAV2 were detected in aqueous humor before treatment. Two patients tested positive for cellular immune response against AAV2 at baseline and after treatment. Humoral immune response was not apparently associated with the dose administered or with the immune status of patients at baseline. No association was found between OISs and serum NAb titers. CONCLUSIONS AND RELEVANCE: In this study, intravitreal administration of rAAV2/2-ND4 in patients with LHON was safe and well tolerated. Further investigations may shed light into the local immune response to rAAV2/2-ND4 as a potential explanation for the observed intraocular inflammation.
引用
- Bouquet C, Vignal Clermont C, Galy A, et al. Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1/2 Clinical Trial. JAMA Ophthalmol. 2019. PMID: 30730541. doi:10.1001/jamaophthalmol.2018.6902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。